Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F.
Millonig A, et al. Among authors: di pauli f.
J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23.
J Neuroimmunol. 2010.
PMID: 20739072